Khondrion

Khondrion is an innovative Dutch biopharmaceutical company focusing on developing small molecule therapeutics for mitochondrial (-related) diseases.  The potential of several lead compounds to serve as new treatment modalities for mitochondrial disease is currently being explored.  Khondrion’s lead compound KH176 has been granted Orphan Drug Designation (ODD) for Leigh disease and MELAS syndrome in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. Thanks to its strategic partnership with the Nijmegen Center for Mitochondrial Disorders of the Radboud University Medical Center, Nijmegen, The Netherlands, Khondrion has access to all mitochondrial tools, technologies and expertise. Besides, Khondrion has established collaborations with patient organizations, patient advocacy groups and university research groups around the world as well as with small, medium and large enterprises. Khondrion has established a strong intellectual property position protecting its emerging product portfolio through the filing of multiple broad patent applications. For more information, please visit www.khondrion.com

Contact Details

Khondrion BV

ATN: Prof. dr. Jan A.M. Smeitink, CEO

Philips van Leydenlaan 15 (west entrance)

6525 EX Nijmegen

The Netherlands

Internal route number 427